ten23 health, a Swiss Contract Development and Manufacturing Organisation (CDMO) for sterile drugs, and SHL Medical, a global provider of drug delivery devices, today announced their strategic partnership to provide a streamlined offering for pharmaceutical and biotech companies that require sterile drug/device combination products.
The partnership will allow SHL Medical to recommend and to integrate seamlessly with ten23 health for drug development and fill & finish, final assembly and final product testing of SHL autoinjectors to customers seeking such CDMO services.
ten23’s end-to-end offering includes formulation and process development, GMP fill & finish of syringes and cartridges, final assembly of autoinjectors and needle-safety devices, product testing and QC.
The integration of ten23's expertise and capabilities with SHL Medical's autoinjector device technology will enhance the customer experience by guiding them through every step of the journey, from initial drug development to the successful commercialisation of specific drug/device combination products.
“We are excited to partner with SHL, broadening our portfolio of device partnerships to deliver integrated patient-centric drug delivery solutions to pharmaceutical companies, tailored for their product needs,” said Prof. Dr. Hanns-Christian Mahler, Chief Enablement Officer of ten23 health. “The combination of strengths in this strategic partnership allows us to offer de-risked services and innovative and reliable drug delivery devices with clear patient focus.”
The collaboration will enable pharmaceutical companies to streamline their drug development processes and bring new therapies to market more efficiently by offering end-to-end solutions from drug formulation to final assembly of SHL Medical’s flagship platform Molly 1ml and 2.25 ml.
“We are pleased to collaborate with ten23 health to complement our drug delivery offering with right-sized customer-focused solutions for small to medium assembly volumes,” said Ulrich Fässler, CEO of SHL. “By working together, we can leverage our combined capabilities to deliver innovative and patient-centric drug delivery solutions that address the evolving needs of the pharmaceutical industry.”
